OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
CVS Caremark (NYSE: CVS) announced today that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the U.S. by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65510-cvs-caremark-to-stop-selling-tobacco-products-at-cvs-pharmacy-locations
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Millennials, health-conscious shoppers and a shift in consumer palates set the stage for what’s to come in the food world this year according to Supermarket Guru, Phil Lempert. For 2014, Lempert, who works closely with ConAgra Foods, Inc. (NYSE: CAG) and its retailers, predicts that the most dramatic food changes will stem from the ever-changing consumer and their relationships with merchants, brands and food.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64398-conagra-food-trend-predictions
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck for Mothers has launched programs aimed at decreasing the number of women across the United States who die from or suffer severe complications related to pregnancy and childbirth.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62776-merck-for-mothers-working-to-reduce-maternal-mortality-rate
The Preeclampsia Foundation today released the Illustrated Preeclampsia Symptoms Tear Pad, a patient education tool that was developed in collaboration with health services researchers at Northwestern University Feinberg School of Medicine in Chicago, Ill. The tool effectively informs pregnant women, even those with potentially poor literacy, about preeclampsia. Because preeclampsia is a disorder that can have grave consequences for a mother and her unborn baby, the goal is for the tool to offer information in a way that allows women to assimilate and retain knowledge related to preeclampsia, leading them to promptly seek medical attention should they have symptoms related to preeclampsia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61626-preeclampsia-foundation-illustrated-symptoms-tear-pad-for-pregnant-women
Starting today, your smart phone can make you smarter about your health. Cigna is launching a new mobile app to help customers take better control of their health and health spending.
Throughout 2013 Cigna will release upgraded app capabilities, including accurate pricing and quality information on doctors and hospitals for more than 200 medical procedures according to the real-time status of the customer’s health plan and available health account funds.
To view Multimedia News Release, go to http://www.multivu.com/players/English/59191-cigna-mobile-app/
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, announced today the launch of the WebMD Pregnancy app, a free iPhone® app offering expectant moms WebMD’s physician-reviewed pregnancy information that is customizable to fit a woman’s unique pregnancy. The WebMD Pregnancy App is WebMD’s latest addition to its multi-screen platform approach which provides actionable health information when consumers want it most, enabling them to better manage their health. WebMD is the leader in mobile for health information, with WebMD’s mobile apps for consumers having been downloaded over 16 million times.1
To view Multimedia News Release, go to http://www.multivu.com/mnr/60045-webmd-launches-new-pregnancy-app-for-iphone
1appFigures data through December 26, 2012; includes WebMD App, WebMD Baby App, WebMD Pain Coach App
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
Millions of families will head to the beach this Memorial Day weekend, many without adequate sun protection. As part of a national effort to reduce the incidence of skin cancer, Neutrogena® is kicking off the 2016 Choose Skin Health® Campaign with a video featuring Brand Ambassador Kristen Bell asking moms everywhere to get real with their kids about the importance of sunscreen—and a pledge to donate $1 for every video share to the non-profit Children’s Melanoma Prevention Foundation.*
Bell’s video acknowledging the challenges moms face tackling serious topics with their children is frank and funny—but skin health is no laughing matter. The fact that only 39% of women and 14% of men use sunscreen regularly is a health issue of national importance when you consider that just one to two severe sunburns can increase lifetime risk of developing melanoma by 40 percent.
The Neutrogena® Choose Skin Health® Campaign was created to change the future of skin health and reduce the risk of skin cancer through education, empowerment, and early detection. This year the brand is developing in-school sun safety programs with the potential to reach 1.6 million students annually with a sun safe behavior curriculum, sponsoring 13,000 free skin cancer screenings annually with charitable partners, and working toward a goal of donating $35 million worth of sunscreen to families in need by the end of 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7847951-neutrogena-choose-skin-health/
